New hope in the fight against lung cancer

Immunotherapy treatment seems able to slow the progression and reduce the risk of recurrence of the most common form of lung cancer, suggests a study in which researchers from three major Montreal hospitals contributed. Used in conjunction with chemotherapy given before surgery and then again after surgery, pembrolizumab also reduced the presence of residual tumours in patients with operable non-small cell lung cancer (NSCLC) and early stage. Some 800 adults with stage II or III NSCLC that could be surgically removed participated in this study, which was conducted at 227 sites around the world, including the McGill University Health Centre, the Center hospitalier de l'Université de Montréal and the St. Mary’s Hospital Center. Forty-six of these patients had been recruited in the Montreal region. Half of the subjects were treated with pembrolizumab before and after surgery to remove the cancer, in addition to chemotherapy. The other half was treated in the same way, but with a placebo. Read: Can dogs really help detect cancer? Event-free survival at 24 months was 62.4% in the pembrolizumab group and 40.6% in the placebo group. Less than or equal to 10% viable residual tumour was observed in 30.2% of members of the pembrolizumab group and 11% of members of the placebo group. No viable residual tumour was seen in 18.1% of members of the first group and in 4% of members of the second. The study’s lead author and surgeon-in-chief, Dr. Jonathan Spicer of the MUHC, said in a statement that “this new treatment is another important step in improving outcomes for patients with this common type. of lung cancer.” The treatment, he added, “is suitable for all patients with stage II or III non-small cell lung cancer whose tumour is operable. On an annual basis, this represents a large number of patients for whom survival will be considerably improved.” Pembrolizumab blocks a protein called PD-1 on the surface of immune system “killer” cells, T cells. This protein prevents T cells from attacking normal cells in the body, which is desirable, but also protects certain cancer cells, which is less so. Blocking PD-1 therefore allows T cells to seek out, attack and destroy cancer cells. It also opens the door to autoimmune adverse effects, but the study authors assure that the “adverse effects resulting from the addition of pembrolizumab were consistent with what has been previously reported in other similar trials combining immunotherapy and surgery.” The findings of this study are published by the prestigious New England Journal of Medicine.

New hope in the fight against lung cancer

Register for free access or login.

Related Topics